Capricor Therapeutics Inc.
CAPR
Capricor Therapeutics, Inc. is a biotechnology company focused on the development and potential commercialization of cell and exosome-based therapeutics for the treatment of Duchenne muscular dystrophy ( DMD ), a rare genetic disorder characterized by progressive muscle degeneration and premature death, as well as other diseases with significant unmet medical need. Since our inception, we have …
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (FY)
$0.00
▼ -100.0% YoY
Net Income (TTM)
-$129M
▼ -159.6% YoY
Op. Margin
–
ROIC
-40.70%
▲ +2.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$115M
▼ -76.7% YoY
Op. Cash Flow (TTM)
-$104M
▼ -74.5% YoY
Net Debt
-$147M
Net Cash Position
Cash & Equiv.
$238M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with CAPR
Held by ETFs
CAPR is in 16 US ETFs. The largest of them, with CAPR's weight in each:
Vanguard Health Care ETFVHT0.01%of the fund
iShares Russell 2000 Growth ETFIWO0.02%of the fund
Fidelity Nasdaq Composite Index ETFONEQ0.00%of the fund
State Street SPDR S&P Biotech ETFXBI0.11%of the fund
Fidelity Enhanced Small Cap ETFFESM0.01%of the fund
Fidelity MSCI Health Care Index ETFFHLC0.00%of the fund
Capricor Therapeutics (CAPR) in three numbers
Questions about Capricor Therapeutics
Is Capricor Therapeutics a high-quality business?
Capricor Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from SEC filings. Its best check is net debt at -$147M, and its weakest is return on capital at -40.7%. The Quality tab shows every check against its target.
Does Capricor Therapeutics (CAPR) pay a dividend?
No. Capricor Therapeutics (CAPR) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 13 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 6 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in CAPR's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing CAPR
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.